243 related articles for article (PubMed ID: 10417495)
21. Rizatriptan: a review of its efficacy in the management of migraine.
Dooley M; Faulds D
Drugs; 1999 Oct; 58(4):699-723. PubMed ID: 10551439
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
[TBL] [Abstract][Full Text] [Related]
23. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females.
Lee Y; Ermlich SJ; Sterrett AT; Goldberg MR; Blum RA; Brucker MJ; McLoughlin DA; Olah TV; Zhao J; Rogers JD
Biopharm Drug Dispos; 1998 Dec; 19(9):577-81. PubMed ID: 9872339
[TBL] [Abstract][Full Text] [Related]
26. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.
Goldstein J; Ryan R; Jiang K; Getson A; Norman B; Block GA; Lines C
Headache; 1998; 38(10):737-47. PubMed ID: 11284462
[TBL] [Abstract][Full Text] [Related]
27. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
[TBL] [Abstract][Full Text] [Related]
28. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder.
Boshuisen ML; den Boer JA
Psychopharmacology (Berl); 2000 Sep; 152(1):74-9. PubMed ID: 11041318
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of rizatriptan in healthy elderly subjects.
Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
[TBL] [Abstract][Full Text] [Related]
30. 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519.
Longmore J; Boulanger CM; Desta B; Hill RG; Schofield WN; Taylor AA
Br J Clin Pharmacol; 1996 Oct; 42(4):431-41. PubMed ID: 8904614
[TBL] [Abstract][Full Text] [Related]
31. Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine.
Klapper JA; O'Connor S
Cephalalgia; 2000 Jul; 20(6):585-7. PubMed ID: 11075843
[TBL] [Abstract][Full Text] [Related]
32. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Deleu D; Hanssens Y
J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
[TBL] [Abstract][Full Text] [Related]
33. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
[TBL] [Abstract][Full Text] [Related]
34. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Williamson DJ; Hill RG; Shepheard SL; Hargreaves RJ
Br J Pharmacol; 2001 Aug; 133(7):1029-34. PubMed ID: 11487512
[TBL] [Abstract][Full Text] [Related]
35. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Rolan P
Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the bioequivalence and pharmacokinetics of two formulations of rizatriptan after single oral administration in healthy volunteers.
Chen J; Jiang WM; Xie YL; Jin L; Mei N; Liang XG
Arzneimittelforschung; 2005; 55(7):355-8. PubMed ID: 16080273
[TBL] [Abstract][Full Text] [Related]
37. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
38. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
de Hoon JN; Willigers JM; Troost J; Struijker-Boudier HA; Van Bortel LM
Clin Pharmacol Ther; 2000 Oct; 68(4):418-26. PubMed ID: 11061582
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
Napier C; Stewart M; Melrose H; Hopkins B; McHarg A; Wallis R
Eur J Pharmacol; 1999 Mar; 368(2-3):259-68. PubMed ID: 10193663
[TBL] [Abstract][Full Text] [Related]
40. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.
Vyas KP; Halpin RA; Geer LA; Ellis JD; Liu L; Cheng H; Chavez-Eng C; Matuszewski BK; Varga SL; Guiblin AR; Rogers JD
Drug Metab Dispos; 2000 Jan; 28(1):89-95. PubMed ID: 10611145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
